Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Cardiol. 2013 Jul;28(4):433-8. doi: 10.1097/HCO.0b013e32836205ff.

Serum urate: a biomarker or treatment target in pediatric hypertension?

Author information

1
Department of Pediatrics, Division of Nephrology, School of Medicine, University of Alabama, Birmingham, Alabama 35233, USA.

Abstract

PURPOSE OF REVIEW:

Studies have shown an association between hyperuricemia and essential hypertension in children, presenting the possibility for serum uric acid level to serve as a biomarker for diagnosis and potential treatment target.

RECENT FINDINGS:

The proposed mechanism of uric acid-induced hypertension is biphasic, with a reversible early phase, implying added significance for new-onset hypertension. Current evidence shows a strong correlation between uric acid level and essential hypertension, supporting its use in diagnosis. Small studies have shown that the use of uric acid-lowering agents allopurinol and probenecid can lower blood pressure in adolescents. These medications require further study in large populations and careful consideration of their side-effect profiles prior to clinical use as antihypertensive agents. Recent studies have also linked dietary fructose intake to hyperuricemia and hypertension, but the clinical effect of fructose reduction on blood pressure has not been confirmed.

SUMMARY:

Current evidence supports use of serum uric acid level as a biomarker for diagnosis of essential hypertension in children. More research is needed to evaluate the utility of pharmacologic and nonpharmacologic means of serum uric acid reduction prior to clinical use as a therapy for hypertension.

PMID:
23736817
DOI:
10.1097/HCO.0b013e32836205ff
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center